完全缓解率（BVAS=0+0 mg GC+无复发）：Benralizumab组23.5% vs 11.1%(p=0.02) 安全性特征：两组不良事件发生率相似; 机制探索发现，Benralizumab通过直接结合IL-5受体(IL-5R)诱导抗体依赖性细胞介导的细胞毒性(ADCC)，可在给药后24小时内将外周血嗜酸性粒细胞降至不可检测水平。

Benralizumab是一款与嗜酸性粒细胞表面表达的IL-5Rα相结合的单克隆抗体。 通过与IL-5Rα相结合，它能够募集天然杀伤细胞，通过诱发嗜酸性粒细胞的 ...

据悉，Benralizumab最初由协和麒麟开发，2006年12月，MedImmune与其达成协议，获得benralizumab在美国、欧洲和其它国家的商业化权益。

SHAMAL研究在重症哮喘治疗方面取得了重大突破。它表明，生物疗法benralizumab使患者能够显著减少或停止使用高剂量吸入类固醇，这是众所周知的严重副作用。通过最大限度地降低与类固醇使用相关的风险，这可能标志着在管理影响全球近3亿人的严重哮喘方面迈出了革命性的一步。

Fasenra的活性药物成分为benralizumab，这是一种单克隆抗体，能够直接结合嗜酸性粒细胞上的白细胞介素5受体的α亚基（IL-5Rα），并独特地吸引自然 ...

Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...

Treatment with benralizumab induced histological remission, defined as an absence of tissue eosinophilia, among patients with eosinophilic gastritis, according to a study published in The Lancet ...

Learn about side effects, uses, dosage, and more for Fasenra (benralizumab), a prescription drug that treats eosinophilic asthma in adults and some children.

Benralizumab generic Benralizumab is a type of monoclonal antibody which is prescribed as an add-on maintenance treatment for treating severe eosinophilic asthma in patients 12 years of age and older.